Showing results (2071-2080 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 30, 2013
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II studyTim Eisen, Yaroslav Shparyk, Nicholas Macleod, et al.
Investigational New Drugs|August 2, 2013
Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatinZhao Hui Li, Qian Zhang, Hai Bin Wang, et al.
Investigational New Drugs|January 1, 1990
Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30W C Rose, G A Basler, P A Trail, et al.
Investigational New Drugs|January 1, 1990
Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)J A Maroun, D J Stewart
Investigational New Drugs|January 1, 1990
Phase I trial of a 5-day course of carbetimerS M Grunberg, E Ehler, R B Francis, et al.
Investigational New Drugs|January 1, 1990
Combination high-dose etoposide and vincristine infusionD V Jackson, J M Cruz, D R White, et al.
Investigational New Drugs|January 1, 1990
Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group studyW A Knight, P Goodman, S A Taylor, et al.
Investigational New Drugs|January 1, 1990
Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanomaS B Kaye, M Clavel, P Dodion, et al.
Investigational New Drugs|June 13, 2012
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumorsChristophe Massard, Jane Margetts, Nadia Amellal, et al.
Investigational New Drugs|October 5, 2013
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomasJörg Thomas Hartmann, M Horger, T Kluba, et al.
Pageof 372